Read More

Viracta Therapeutics Announces Interim Data From Phase 1b/2 Clinical Trial Of Nana-val In Patients With Epstein-Barr Virus-Positive Solid Tumors That Show Confirmed Tumor Responses At Higher Dose Levels

Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher

VIRX

Read More

Aptar Awarded U.S. FDA Contract To Study Opportunities For Low Global Warming Potential Propellants For Metered Dose Inhalers; The Contracted Work, Including “Optional Contract Line Items”, Is Valued At Up To ~ $6M

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges

ATR

Read More

Why Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with 

EYPT

Read More

Top Contenders Emerge in Johnson & Johnson’s Race for New CEO, Plans Under Spotlight After Unexpected Departure

The race for Johnson & Johnson's (NYSE: JNJ) top executive position has intensified following the unexpected exit of Ashley McEvoy, the former head of the company's medical device unit, potentially altering the anticipated succession plans within the healthcare giant

JNJ